JenniferM.RosenbluthMD

Physician

Dr. Rosenbluth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2013 - 2017
Massachusetts General HospitalResidency, Internal Medicine, 2011 - 2013
Vanderbilt University School of MedicineClass of 2011

PubMed

Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
Kirithiga Ramalingam, Rachel Woody, Alexa Glencer, Christopher J Schwartz, Hidetoshi Mori
JAMA Oncology. 2025-03-01
3 citations
Implantation of engineered adipocytes suppresses tumor progression in cancer models.
Hai P Nguyen, Kelly An, Yusuke Ito, Bhushan N Kharbikar, Rory Sheng
Nature Biotechnology. 2025-02-04
1 citations
T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.
Nam Woo Cho, Sophia M Guldberg, Barzin Y Nabet, Jie Zeng Yu, Eun Ji Kim
Cancer Immunology Research. 2025-02-03

Experimental Treatment Uses Engineered Fat Cells to “Starve” TumorsMarch 27th, 2025
CRISPR Transforms Ordinary Fat Cells into Cancer Killing MachinesFebruary 25th, 2025
Engineered Adipocytes Target Tumor Growth in Cancer ModelsFebruary 6th, 2025
Join now to see all

Developing liquid biopsy tests for malignant effusions using artificial intelligence-assisted, morphology-based isolation of tumor cellsUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
In vitro models as a window to learn how to change outcomes in women at high risk of developing breast cancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027